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Fascin-1, the most expressed form of fascin in vertebrate tissues, is an actin-bundling protein that induces cell membrane protrusions
and increases motility of normal and transformed epithelial cells. Very few data are available on the role of this protein in nonsmall cell
lung cancer (NSCLC). Two hundred and twenty patients with stage I NSCLC and long-term follow-up were evaluated
immunocytochemically for fascin expression. Overall, variable fascin immunoreactivity was detected in 98% of 116 squamous cell
carcinomas, in 78% of 96 adenocarcinomas, in 83% of six large cell carcinomas, and in the two adenosquamous carcinomas under
study. Neoplastic emboli were commonly decorated by the antifascin antibody (Po0.001), also when the surrounding invasive
carcinoma was unreactive. Fascin immunoreactivity correlated with high tumour grade (P¼0.017) and, in adenocarcinomas, with high
Ki-67 labelling index (P¼0.021). Adenocarcinomas with a prevalent bronchiolo-alveolar in situ component were less commonly
immunoreactive for fascin than invasive tumours (P¼0.005). Contralateral thoracic or distant metastases were associated significantly
with diffuse (460% immunoreactive tumour cells) fascin expression in adenocarcinomas (P¼0.043), and marginally with strong
fascin immunostaining in squamous cell carcinomas (P¼0.13). No associations were noted with any other clinicopathological
variables tested. Patients with tumours showing diffuse (460% immunoreactive neoplastic cells) and/or strong immunoreactivity for
fascin had a shorter survival (P¼0.006 for adenocarcinomas and P¼0.026 for squamous cell carcinomas), even after multivariate
analysis (P¼0.014 and 0.050, respectively). The current study documents for the first time that fascin is upregulated in invasive and
more aggressive NSCLC, being an independent prognostic predictor of unfavourable clinical course of the disease. Targetting the
fascin pathway could be a novel therapeutic strategy of NSCLC.
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Lung cancer is one of the leading causes of morbidity and death
worldwide. Patients with pathological stage I nonsmall cell lung
cancer (NSCLC), however, have the best life expectation, because
they lack major adverse prognostic factors, as incomplete surgical
resection and lymph node or distant metastases. The current
standard treatment for these patients is complete removal of the
primary tumour without any additional adjuvant therapy. The
long-term survival rate, however, is only from 55 to 72%, mainly
because of the occurrence of local relapses and distant metastases
(Nesbitt et al, 1995; Mountain, 1997; D’Amico et al, 1999).
Interaction among cancer cells, extracellular matrix proteins,
and endothelial cells plays a fundamental role in the development
of local invasion and distant metastases (Aznavoorian et al, 1993;
Alessandro et al, 1996; Liotta and Kohn, 2001). Invasive tumour
cells are often characterised by changes in cell shape with the
appearance of membrane protrusions, loss of anchorage depen-
dency, and loss of cell–cell adhesion and junctional communica-
tions. Many of these changes are because of rearrangements of the
cytoskeletal microfilaments due to the action of several types of
actin cross-linking proteins (Maekawa et al, 1988; Tilney et al,
1998).
Among these molecules, fascins (reviewed by Kureishy et al,
2002) are implied in the organisation of two major forms of actin-
based structures that include either cortical cell protrusions, such
as filopodia, spikes, lamellipodial ribs, dendrites and microvilli, or
cytoplasmic microfilament bundles (Kureishy et al, 2002). The
former structures are thought to play an active role in cell–matrix
adhesion, cell interactions and cell migration, whereas the latter
participate in maintaining cell architecture (Kureishy et al, 2002).
In humans, three different forms of fascin are currently known,
referred to as the vertebral fascin or fascin-1, the retinal fascin or
fascin-2 (with 56% of homology to fascin-1), and the testis fascin
as fascin-3 (with 27% homology to fascin-1). While fascin-1 is
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ydistributed in most vertebrate tissues, fascin-2 is circumscribed to
the retina (Tubb et al, 2000; Wada et al, 2001), and fascin-3 is
expressed specifically in the testis (Tubb et al, 2002). The human
fascin-1 gene (FSCN1), located at chromosome 7q22 (Duh et al,
1994), encodes for an evolutionarily highly conserved 55-kDa
actin-bundling protein (Duh et al, 1994; Mosialos et al, 1994;
Yamashiro-Matsumura and Matsumura, 1985) that induces
membrane protrusions at the leading edges of the cells and greatly
increases cell motility (Tao et al, 1996; Adams, 1997; Yamashiro
et al, 1998). This protein is normally expressed by cells
characterised by different types of membrane protrusions, such
as neurons, glial cells and dendritic cells (Mosialos et al, 1994; Ross
et al, 1998, Al-Alwan et al, 2001; Cohan et al, 2001), or by actively
migrating cells, such as endothelial cells of the microvessels, which
are extensile cells capable of migrating during angiogenesis
(Mosialos et al, 1994; Tao et al, 1996, Pinkus et al, 1997; Hu et al,
2000). In normal epithelial cells, the fascin-1 expression level (later
on indicated as fascin only) is usually low, but is often upregulated
in several types of human neoplasms, such as breast (Sun et al,
1997; Grothey et al, 2000a,b; Guvakova et al, 2002), ovary (Hu et al,
2000) and pancreas carcinomas (lacobuzio-Donahue et al, 2002;
Maitra et al, 2002), and skin tumours (Goncharuk et al, 2002).
Very few data, however, are available on fascin expression in
NSCLC. Recently, Del Rosario et al (2001) have reported in
abstract form that fascin immunoreactivity correlates with tumour
grade, but not tumour stage, death rate and survival of NSCLC
patients. In the present study, we first investigated fascin
immunoreactivity in NSCLC, comparing two different commer-
cially available monoclonal antibodies in a retrospective series of
220 chemotherapy-naive patients with stage I disease. We
document that fascin is overexpressed by most NSCLC, correlates
with a tumour invasive phenotype, and is an independent
prognostic indicator of reduced survival.
MATERIALS AND METHODS
Patients
The study population includes 220 unselected consecutive patients
(199 males and 21 females) with stage I NSCLC treated at the
Department of Thoracic Surgery of the ‘Ospedale Civile Maggiore’
in Verona (Italy) between 1987 and 1993. For each case, all paraffin
blocks were retrieved and original haematoxylin and eosin-stained
sections reviewed. Complete clinical follow-up for survival analysis
was available for all patients, with a mean duration of 75.7744.4
months (median 80 months; range 2–159 months). Recurrent
disease was observed in 109 (49.5%) patients and 91 (41.4%) died
of the disease.
Inclusion criteria for entry into the study included p-stage IA
(95 men and 11 women) and IB (104 men and 10 women)
according to the revised international system for staging lung
cancer (Mountain, 1997), radical surgery, no (neo)-adjuvant
therapy, a minimum 30-day postoperative survival, and a
minimum follow-up of 5 years.
The patients’ age ranged from 35 to 80 years for men
(mean7s.d.: 62.578.3 years; median: 63 years) and from 47 to
76 years for women (mean7s.d.: 61.377.3 years; median: 62
years). According to previously refined pathological criteria for
lung tumours (Travis et al, 1999), there were 116 (52.7%)
squamous cell carcinomas, 96 (43.6%) adenocarcinomas, six
(2.8%) large cell carcinomas, and two (0.9%) adenosquamous
carcinomas. Subtyping of adenocarcinomas was performed
according to the WHO and Shimosato’s classifications (Shimosato,
1994; Travis et al, 1999). Eleven (5.0%) carcinomas were well
differentiated (10 adenocarcinomas and one squamous cell), 121
(55.0%) moderately differentiated (76 squamous cell, 43 adeno-
carcinomas, and two adenosquamous), and 88 (40.0%) poorly
differentiated (43 adenocarcinomas, 39 squamous cell, and six
large cell carcinomas). In homolateral thoracic recurrences there
was a prevalence (17 out of 23) of adenocarcinomas, and in
controlateral thoracic recurrences a prevalence (19 out of 27) of
squamous cell carcinomas, whereas distant metastases were almost
equally distributed between the two tumour types (24 out of 52 vs
28 out of 52) respectively: w
2¼9.908, P¼0.007). Complete
information about the smoking history of the patients was not
available at the time of the present study.
Immunocytochemistry and evaluation of data
Formalin-fixed and paraffin-embedded tissue samples obtained at
surgery were investigated. Tumours up to 2cm in size were
entirely embedded and immunostained; at least two representative
tissue blocks were investigated in larger neoplasms. Samples of
normal pulmonary parenchyma from patients with unrelated,
nonmalignant lung diseases, and peritumoural lung tissue from the
same cohort of NSCLC patients provided the control groups for
noncarcinoma and carcinoma patients, respectively.
Fascin was immunolocalised on 4mm-thin tissue sections using
two monoclonal antibodies, clone IM20 (Novocastra Laboratories,
Newcastle upon Tyne, UK) that recognises the C-terminal region of
the molecule, and clone 55k-2 (Dako, Glostrup, Denmark) that
reacts with a 55-kDa protein in Western blots of HeLa, normal rat
kidney and gerbil fibroma cell lysates (Yamashiro-Matsumura and
Matsumura, 1986). The latter antifascin antibody was also found to
immunoblot bacterially expressed human homolog singed gene
(hsn) product and a 55-kDa protein from cell lysates of peripheral
blood dendritic cells (Duh et al, 1994; Mosialos et al, 1996). The
specificity of the clone IM20 has been evaluated on human tonsil
for Western blot analysis, with a molecular weight detected at
approximately 55-kDa (Novocastra Laboratories, personal com-
munication, 2002, Figure 1). After blockage of endogenous
peroxidase activity with 5% hydrogen peroxide and heat-mediated
antigen retrieval with 1mM EDTA pH 8 (Sigma Chemical Co.,
St Louis, MO, USA) in a microwave oven at 750W for 12min, the
sections were reacted overnight at 41C with the primary antibodies
at a dilution of 2.5mgml
 1 in Tris-buffered saline. Detection steps
were performed using a commercially available kit (Dako EnVision
Plus-HRP, Dako), according to the manufacturer’s instructions.
Peroxidase activity was developed with 3,30-diaminobenzidine-
copper sulphate (Sigma Chemical Co., St Louis, MO, USA) to
obtain a brown–black end product. Tumour proliferative fraction
was assessed by Ki-67 immunostaining and the percentage of
reactive cells was recorded as the labelling index (Pelosi et al,
1996).
To colocalise fascin and Ki-67 antigen on the same tumour
samples, representative blocks of NSCLC were double stained for
fascin using the 55k-2 clone and for Ki-67 antigen. After overnight
reaction with fascin and development with the Dako EnVision
Plus-HRP kit and 3-amino-ethylcarbazole (Sigma) as a chromogen
to yield a red end product, tissue sections were reacted with Ki-67
antigen (clone Mib-1, Immunotech, Marseille, France, 10mgml
 1)
for 1 h at room temperature. Detection was performed using the
Dako EnVision Plus-HRP kit and 3,30-diaminobenzidine-copper
sulphate to obtain a brown–black end product. This labelling
procedure was chosen because nuclear antigens, such as Ki-67, are
best highlighted in double-imunostaining experiments if devel-
oped in a more brilliant black–brown product, whereas cytoplas-
mic antigens may be easily evidenced also using a lighter red
development. Microwave oven heating at 750W for 5min was used
to block the residual enzyme activity after the first development
reaction (Lan et al, 1995). Vascular invasion in NSCLC was
highlighted by CD34 immunostaining of endothelial cells using
standard immunohistochemical methods. The specificity of all
immunoreactions was double-checked by substituting the primary
antibodies with nonrelated isotypic mouse immunoglobulins at a
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Immunoreactivity of macrophages, dendritic cells of the bronchus-
associated lymphoid tissue, and endothelial cells of microvessels
was used as internal positive controls for fascin.
Two observers (GP and AS) evaluated fascin immunoreactivity
of tumour cells independently and blindly, without knowledge of
the patients’ identity or clinical outcome. Results were expressed
semiquantitatively: as negative to low immunoreactivity, if staining
was either completely absent or observed in less than 5% of cells;
as moderate immunoreactivity if staining was observed in 5–60%
of tumour cells; and as high immunoreactivity if staining was
recognised in more than 60% of tumour cells. Also, the intensity of
fascin immunostaining was simulataneously graded as low if a
faint to distinct granular labelling was detectable throughout the
cytoplasm, but less intense than seen in the normal internal
controls (endothelial and dendritic cells), or strong if it was of the
same or greater intensity than the latter.
Statistical analysis
Associations of categorical variables were evaluated by Fisher’s
exact t-test or w
2 test (applying Yates’ correction for continuity).
All correlation tests were performed using Spearman’s rank test
(r). Intra- and interobserver reproducibility between two indepen-
dent observers was assessed as previously reported in detail (Pelosi
et al, 1996). Differences in immunostaining between the two
antibodies in the whole series of NSCLC were evaluated with
Wilcoxon’s signed-rank test for pairs. Survival estimates were
calculated with Kaplan–Meier’s method and compared by Cox–
Mantel’s log rank test. The comparative importance of explanatory
variables on survival time was evaluated by means of Cox’s
proportional hazard regression model. The following variables
were examined for overall (OS) and disease-free survival (DFS)
analysis: age, sex, performance status, clinical symptoms, tumour
grade, tumour size, pathological stage, proliferative fraction, and
vascular invasion. All the analyses were performed using the SAS
statistical software (SAS Institute, Inc., Cary, NC, USA). All P-
values were based on two-sided testing.
RESULTS
Fascin immunoreactivity appeared as a fine, granular to diffuse
cytoplasmic staining, in both normal and neoplastic cells. IM20
and 55k-2 monoclonal antibodies did not differ significantly with
regard to both the number of immunoreactive cells as evaluated
semiquantitatively using three scoring categories (P¼0.75) and
the immunostaining intensity as evaluated in two subjective
categories by comparison with internal positive controls
(P¼0.31) (Figure 2 A, B). Accordingly, very high correlation was
noted between the two antibodies for both evaluation systems of
immunoreactivity (r¼0.95 for the number of immunoreactive
cells, Po0.001; r¼0.91 for the immunostaining intensity,
Po0.001).
In the normal lung, fascin immunoreactivity was invariably
found in endothelial cells of the microvessels in the bronchial and
alveolar walls, in dendritic cells of the mucosa-associated
lymphoid tissue, and in tissue macrophages. Endothelial cells of
major pulmonary vessels and bronchial and alveolar epithelia were
consistently unreactive, although the basolateral membranes of
bronchial epithelial cells were occasionally decorated by the
antiserum. No differences in fascin immunoreactivity were seen
in the normal pulmonary parenchyma from patients with
unrelated, nonmalignant lung diseases, and in the peritumoural
lung tissue from the same cohort of NSCLC patients.
Overall, fascin immunoreactivity was detected in 196 out of 220
(89%) NSCLC, including 75 out of 96 (78%) adenocarcinomas, 114
out of 116 (98%) squamous cell carcinomas, five out of 6 (83%)
large cell carcinomas, and the two adenosquamous carcinomas
investigated (w
2¼22.4, Po0.001). Independent of tumour type,
fascin-immunoreactive tumours showed heterogeneity both in the
percentage of labelled cells and in the intensity of immunostaining
(Table 1 and Figure 2 C–J). Immunoreactivity was sometimes
markedly enhanced at the tumour–host interface, whereas horn
pearls of squamous cell carcinomas were less immunoreactive than
adjacent neoplastic nests. A close correlation was found between
the percentage of fascin-immunoreactive cells and the staining
intensity within individual tumours (r¼0.79, Po0.001). Evalua-
tion of intraobserver reproducibility did not show significant
differences among the different tumour types, and a high
interobserver correlation was noted in both scoring fascin
immunoreactive cells and grading the intensity of immunostaining
(r¼0.96, Po0.001).
Adenocarcinomas with prevalent (X70%) bronchiolo-alveolar
component were less commonly (two out of seven cases)
immunoreactive for fascin (Figure 2, H, I) than those with
prevalent invasive components of acinar (18 out of 23) papillary
(24 out of 31), or solid (28 out of 31) types (w
2¼19.44, P¼0.005)
(Figure 2, F, G). The bronchiolo-alveolar in situ component at the
periphery of adenocarcinomas also was less immunoreactive for
fascin than the invasive components of acinar, papillary, or solid
types (Figure 2I). Reduced fascin imunoreactivity was more
commonly encountered in the case of nonmucinous (16 out of
22 cases) than in mucinous (one out of 5 cases) bronchiolo-
alveolar patterns (P¼0.047), even though the former could show
occasional fascin immunoreactivity (Figure 2J).
AB
Fascin
97.4kD
66.2kD
45.2kD
31.0kD
21.0kD
Figure 1 Western blot analysis of human tonsil using NCL-fascin (clone
IM20). Lane A, molecular weight markers. Lane B, tonsil immunoblotted
with NCL-FASCIN antibody. This image was supplied by courtesy of
Novocastra Laboratories Ltd, Newcastle upon Tyne, UK.
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histological field of NSCLC: both tumour cells (white triangles) and normal endothelial cells (arrows) are similarly highlighted by the two reagents with no
significant differences. Squamous cell carcinomas usually show diffuse immunostaining for fascin (C), whereas horn pearls are less immunoreactive (D). Only
rarely squamous cell carcinomas lack fascin expression: in these cases, immunoreactivity of endothelial cells serves as internal positive control (E). (Panels C
and D represent different areas of the same squamous cell carcinoma according to the different differentiation grade, whereas panel E refers to another case
of squamous cell carcinoma showing very poor differentiation). In adenocarcinomas, invasive patterns of papillary (F) and solid (G) types show commonly
immunolabelling for fascin, whereas the bronchiolo-alveolar pattern, either nonmucinous or mucinous (H), is generally unreactive for fascin even when this
component is present in mixed forms along with an invasive pattern of acinar type (I). Nonmucinous type, however, may show occasional immunoreactivity
for fascin (J). (Panels F–Jbelong to different cases of adenocarcinoma). (A: 55k-2 monoclonal antibody; B–J: IM20 monoclonal antibody. All immunostains
were performed with diaminobenzidine, and then counterstained with haematoxylin. Scale bars are reported in the bottom on the left of every panel.)
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carcinomas) showed vascular invasion, highlighted by CD34
immunostaining of endothelial cells. The neoplastic emboli were
intensely labelled by the anti-fascin antibody (Figure 3 A, B),
independent of the staining intensity of the surrounding tumour
cells (Figure 3A, inset), and were often conatined in CD34-
immunoreative sinusoidal spaces (Figure 3C). Of these 65 tumours,
57 (26 adenocarcinomas and 31 squamous cell carcinomas)
showed immunostaining of both the neoplastic emboli and of
the invasive neoplastic nests, whereas eight out of 65 tumours (all
adenocarcinomas) did not show any fascin immunoreactivity in
either component (Po0.001). Contralateral thoracic or distant
metastases (32 out of 79 in adenocarcinomas and 47 out of 79 in
squamous cell carcinomas, P¼0.23) were associated significantly
with diffuse (460% immunoreactive tumour cells) fascin expres-
sion in adenocarcinomas (P¼0.043), and marginally with strong
fascin immunostaining in squamous cell carcinomas (P¼0.13).
Well-differentiated NSCLC considered as a whole were more
commonly (five out of eight cases) fascin-negative, whereas poorly
differentiated tumours more often (46 out of 57 cases) exhibited
Figure 3 (A–D) Neoplastic emboli (asterisks) within vascular channels (arrows) of both squamous cell carcinoma (two tumour nests infiltrating the
stroma are also present on the right of the figure) (A) and adenocarcinomas (B). Tumour emboli are strongly immunoreactive for fascin, even when the
remainder tumour is negative for the marker (A, inset). In a case of adenocarcinoma, the same sinusoidal space, engulfed by tumour cells (asterisks), is
delimited by CD34-positive endothelial cells (black triangles) and strongly reacts for fascin (C). Double immunostaining for fascin (red) and Ki-67 antigen
(black–brown) shows that highly proliferating tumour cell foci (asterisks) are downregulating fascin expression, whereas adjacent neoplastic nests show
either lower proliferative activity (black triangles) or strong immunoreactivity for fascin (D). (A–D: IM20 monoclonal antibody; in D, also Mib-1 monoclonal
antibody. Immunoperoxidase staining was performed with diaminobenzidine to obtain a black–brown end product (A–D) or amino-ethylcarbazole to
obtain a red end product (D), and then counterstained with haematoxylin. Scale bars are reported in the bottom on the left of every panel.)
Table 1 Distribution of fascin immunoreactivity in the 220 NSCLC
Immunoreactive cells (%)
a Immunolabelling intensity (%)
b
Histotype None 5–60% >60% None Low High
Adenocarcinoma (N=96) 21 (22) 41 (43) 34 (35) 21 (22) 43 (45) 32 (33)
Adenosquamous (N=2) 0 (0) 0 (0) 2 (100) 0 (0) 0 (0) 2 (100)
Squamous cell carcinoma (N=116) 2 (2) 14 (12) 100 (86) 2 (2) 45 (47) 69 (72)
Large cell carcinoma (N=6) 1 (17) 1 (17) 4 (66) 1 (17) 0 5 (83)
a w
2=61.8, Po0.001.
b w
2=34.7, Po0.001.
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Figure 4 (A,B) Overall and disease-free survival curves according to the number of fascin-immunoreactive tumour cells (A) and immunostaining intensity
(B) in both adenocarcinomas and epidermoid or squamous cell carcinomas.
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(P¼0.017). In adenocarcinomas, the percentage of fascin-immuno-
reactive cells correlated significantly with the Ki-67 labelling index
(P¼0.021), whereas this correlation was weaker in squamous cell
carcinomas (P¼0.14). When stratified for fascin levels of
immunostaining, adenocarcinomas with high (460%) fascin
immunoreactivity exhibited more pronounced proliferative activ-
ity (mean7s.d.: 27.9716.5%; median: 27%) than tumours with
negative to low (up to 30%) fascin immunoreactivity (mean7s.d.
20.4713.4%; median: 20%) (P¼0.028). This association, however,
evidenced a wide dispersion of the values, as shown by their low
correlation coefficient (r¼0.23, d.f.¼94). As a matter of fact,
double-immunostaining experiments indicated that the number of
fascin-positive cells was usually by far higher than Ki67-positive
cells within individual tumours, whereas nests of actively
proliferating tumour cells showed a consistent decrease of fascin
immunoreactivity (Figure 3D). No other associations with gender,
age, clinical symptoms, and performance status of the patients, or
with tumour diameter, pathological stage, and cell subtyping were
observed.
Patients with tumours showing diffuse (i.e. in more than 60%
neoplastic cells) or strong immunoreactivity for fascin had shorter
OS (P¼0.006 for adenocarcinomas and P¼0.026 for squamous
cell carcinomas) and DFS (P¼0.013 and 0.024, respectively)
(Figure 4 A, B). Other prognostic factors were tumour stage and
diameter, performance status, and clinical symptoms (Table 2).
Multivariate analyses showed that diffuse fascin immunoreactivity,
performance status, and clinical symptoms were independent
prognostic factors for both OS and DFS in patients with
adenocarcinomas. Conversely, strong fascin immunostaining and
vascular invasion emerged as independent prognostic factors in
patients with squamous cell carcinomas (Table 3).
DISCUSSION
The current investigation documents that fascin is upregulated in
most (89%) NSCLC, and correlates with higher tumour grade and
higher proliferative fraction. Diffuse or intense fascin immuno-
reactivities are independent unfavourable prognostic factors in
patients with adenocarcinoma and squamous cell carcinomas,
respectively. Finally, our data suggest that fascin is likely involved
in tumour invasiveness and vascular invasion.
This is, to our knowledge, the first study in which the
immunoreactivities of two different, commercially available
monoclonal antibodies against fascin are evaluated on the same
large series of human carcinomas. In our study, the IM20 clone
gave the same brilliant decoration of targeted cells as 55k-2 (Figure
2A, B), and the final results within individual tumours did not
change significantly between the two reagents in terms of both
number of immunoreactive cells as evaluated semiquantitatively in
three categories (negative to low, moderate and high) and intensity
of immunostaining as assessed in two subjective categories (low or
strong) in comparison with the consistent immunoreactivity of
positive internal controls (endothelial cells). More importantly, the
clinicopathological and prognostic implications did not change for
both reagents, inasmuch as the results for each antibody within
individual tumours fell into the same category of immunostaining.
Therefore, we indicate that both antibodies are excellent and
highly reproducible reagents for immunodetecting fascin on
paraffin sections, and that both are equally suitable for studying
fascin expression in lung pathology.
The high prevalence of fascin immunoreactivity in NSCLC (as
opposed to the lack of staining of nonneoplastic epithelia of the
lower respiratory tract) and its significant relation with tumour
recurrence and reduced patient survival emphasise the possible
involvement of this protein in the development and progression of
NSCLC. To our knowledge, this is the first study in which a large
series of stage I NSCLC with long-term follow-up has been
investigated for fascin immunoreactivity. Recently, Del Rosario
et al (2001) have reported in abstract form only that fascin
immunoreactivity was detectable in 31% of 55 adenocarcinomas
and 89% of 55 squamous cell carcinomas, correlating significantly
with high tumour grade in the former and low tumour grade in the
latter. No relation was noted, however, with tumour stage or
patient survival. The comparison of the data is hampered by the
lack of details on the evaluation of immunostaining and on the
stage distribution of the patients in the previous series. Other
studies on patients with breast and ovarian cancers have failed to
demonstrate any definite relation between fascin immunoreactivity
and tumour grade (Grothey et al, 2000b; Hu et al, 2000). In breast
cancer patients, however, fascin immunoreactivity was more
prevalent in nondiploid and highly proliferating tumours with a
negative hormone receptor status and Her2/neu overexpression
(Sun et al, 1997; Grothey et al, 2000a,b), while in ovarian cancer it
was correlated with advanced disease stage (Hu et al, 2000).
Recently, Yamashiro et al (1998) have reported that fascin
transfection or protein microinjection into normal epithelial or
mesenchymal cell lines induced remarkable changes in cell
morphology, with the emission of microspikes on apical surfaces,
extended lamellipodia at the basolateral surfaces, and disruption of
cell–cell contact. This supports the view that fascin overexpression
may ultimately affect the differentiation (and hence the grade) of
lung tumours via the remodelling of the cell shape and volume,
and the changes in cell motility and aggregation status.
The prognostic power of tumour grade, growth patterns
(Pastorino et al, 1997; Travis et al, 1999), and cell subtyping
(Shimosato, 1994) in NSCLC is highly controversial. Fascin
immunoreactivity may thus be considered a more reliable tool
for better assessing the biological aggressiveness and clinical
course of NSCLC. Furthermore, the inhibition of fascin activity by
phosphorylation (Yamakita et al, 1996, Ono et al, 1997, Tilney et al,
1998; Adams et al, 1999, Cohan et al, 2001) or antisense
oligonucleotide strategy (Al-Alwan et al, 2001) could represent
potentially novel therapeutic options in the treatment of lung
cancer. The validation of differentially expressed fascin levels in
NSCLC could open new diagnostic and therapeutic perspectives,
such as the development of radiologic imaging systems based
on tagged antibody strategy to detect small lung cancers,
either primary or metastatic, or the strategy of cell-mediated or
antibody-based immunotherapy using fascin for targeting more
aggressive lung carcinomas.
An interesting aspect of our investigation is the relation between
fascin immunoreactivity and proliferative activity of tumour cells.
Collectively considerated, tumours with high (460%) fascin
immunoreactivity showed significantly greater Ki-67 labelling
index (mean7s.d.: 27.9716.5%; median: 27%) than tumours with
negative to low (up to 30%) fascin immunoreactivity (mean7s.d.:
20.4713.4%; median: 20%) (P¼0.028). The wide dispersion of
values in the correlation test (r¼0.23), however, indicated that
probably there is no linear relation between the two markers, and
that this association may depend on the higher tumour grade of
fascin overexpressing adenocarcinomas. In fact, a closer positive
relation was found between Ki-67 labelling index and tumour
grade (r¼0.44, Po0.001) (data not shown). As a matter of fact
double immunolabelling experiments of individual tumours
indicated that foci of actively proliferating tumour cells were less
immunoreactive for fascin than adjacent tumour nests showing a
lower proliferative activity. This could imply that cycling cells (like
those collectively highlighted by the Ki-67 antigen) may transito-
rily downregulate fascin, with no apparent differences in
immunostaining being appreciable between tumour cells clearly
showing mitotic figures (corresponding to the M phase) and
tumour cells in the other phases of the cell cycle (G1, G2 and S).
The precise molecular mechanisms and the role of fascin
expression in relation to the cell cycle of NSCLC still remain to
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ybe explained. Previous data by Duh et al (1994), however,
indicated that fascin mRNA was highly expressed in actively
growing renal carcinoma cell lines and in activated, but not in
resting, lymphocytes, suggesting a functional role for this protein
in proliferation. Likewise, Guvakova et al (2002) recently reported
that the activation of insulin-like growth factor (IGF)-I receptor
signalling is associated with the induction of fascin spikes and
ruffles in breast cancer cell lines, without altering the protein
levels. Interestingly, several lines of evidence implicate IGFs and
their cognate receptors in proliferative and antiapoptotic effects of
many human malignancies, including NSCLC cell lines (Lee et al,
2002). Therefore, we cannot exclude that other regulatory
mechanisms may be involved in pulmonary adenocarcinomas, to
explain our apparently conflicting findings of fascin downregula-
tion in actively proliferating tumour cells when evaluated within
individual tumours using the double immunostaining strategy.
Further work is in progress in our laboratory to analyse this
interesting point.
Bronchiolo-alveolar carcinomas are considered to be noninva-
sive tumours with lepidic spread along the alveolar septa (Travis
et al, 1999). In our study, bronchiolo-alveolar components, with or
without collapse of the underlying stroma (Noguchi et al, 1995),
were consistently devoid of fascin immunoreactivity, contrasting
with the adjacent invasive components of acinar/tubular or
papillary types. The reasons of the differential distribution of
fascin immunoreactivity in mucinous and nonmucinous bronch-
iolo-alveolar carcinomas, however, still remain elusive. Likewise,
the protein was scarcely expressed in squamous cell dysplasia and
in situ squamous cell carcinomas at different anatomical sites
(cervix, larynx, lung, and skin) (data not shown), supporting the
view that fascin upregulation is a late event in the sequential
pathogenesis of NSCLC. The molecular mechanisms, however,
leading to fascin upregulation in these tumours are presently
unknown. Some studies have suggested that Her-2/Neu over-
expression may increase fascin mRNA and protein levels in human
breast cancer cell lines (Grothey et al, 2000a), but we have been
Table 2 Univariate prognostic value of tumour variables for survival
Adenocarcinoma Squamous cell carcinoma
Variables Categories OS DFS OS DFS
Sex M/F 0.1993 0.0632 0.4113 0.7377
Age Continuous 0.8378 0.1045 0.8748 0.2793
Tumour grade G1/G2/G3 0.6593 0.3657 0.2807 0.1915
Tumour stage T1a/T1b 0.0466 0.1754 0.4964 0.1248
Tumour diameter Continuous 0.0236 0.0565 0.0752 0.0188
Performance status Continuous o0.0001 0.0005 0.5026 0.5629
Symptoms No/local/general 0.0002 0.0004 0.2854 0.3134
Ki-67 Continuous 0.2653 0.4655 0.2551 0.0910
Vascular invasion Present vs absent 0.8723 0.9899 0.0202 0.0156
Fascin-reactive cells None/5–60%/>60% 0.0062 0.0132 0.2367 0.1852
o5% vs >60% 0.0129 0.0219 – –
Fascin intensity None/low/high 0.0063 0.0260 0.0266 0.0245
Fascin intensity: None, no immunoreactivity; low, weak to moderate immunoreactivity; high: intense immunoreactivity.
Table 3 Multivariate analysis
Variables Categories HR
a 95% CI
a P value
Adenocarcinomas
Age Continuous 0.97 0.94–1.01 0.0957
Sex F vs M 0.39 0.13–1.17 0.0916
Fascin-reactive cells o5% vs >60% 4.48 1.35–14.9 0.0144
Tumour grade G1/G2/G3 0.74 0.40–1.36 0.3303
Tumour stage T1B vs T1A 1.82 0.42–7.83 0.4213
Tumour diameter Continuous 0.79 0.17–3.73 0.7649
Performance status Continuous 0.94 0.89–0.99 0.0233
Symptoms Present vs absent 2.96 1.07–8.22 0.0368
Vascular invasion Present vs absent 1.23 0.59–2.57 0.5901
Ki-67 index Continuous 1.01 0.99–1.03 0.1553
Squamous cell carcinomas
Age Continuous 1.02 0.98–1.06 0.3874
Sex F vs M 0.79 0.18–3.37 0.7450
Fascina intensity High vs low 1.83 1.00–3.35 0.0516
Tumour grade G1/G2/G3 1.02 0.57–1.83 0.9518
Tumour stage T1B vs T1A 0.98 0.37–2.56 0.9612
Tumour diameter Continuous 1.11 0.88–1.40 0.3914
Performance status Continuous 1.01 0.97–1.04 0.6433
Symptoms Present vs absent 1.42 0.68–2.96 0.3562
Vascular invasion Present vs absent 1.19 1.01–3.62 0.0481
aHazards ratio (HR) and 95% confidence intervals (CI) were obtained from a Cox proportional regression model.
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protein or gene status in our series of NSCLC, using both
immunohistochemistry for protein overexpression and FISH
analysis for gene amplification or polysomy (data not shown).
Functional interactions with extracellular matrix molecules pro-
vide further mechanisms for the cellular regulation of fascin,
although these adhesion conditons do not upregulate the protein
but rather alter its subcellular distribution, either inducing or
stabilising bundling of actin by fascin, or not supporting fascin
protrusions (Kureishy et al, 2002). At present, evidence that fascin
– a marker of tumour aggressiveness – gets turned on in NSCLC by
means of the contact with extracellular matrix moieties is poor. On
the contrary, some studies have recently reported that the
downregulations of thrombospondin-1 (Yamaguchi et al, 2002)
or tenascin-C (Cai et al, 2002), two molecules of extracellular
matrix supporting the formation of large arrays of fascin
microspikes and ribs at cell margins and in lamellipodia (Adams,
1995; Fischer et al, 1997; Adams and Schwartz, 2000; Anilkumar
et al, 2002), are instead associated with poor prognosis and tumour
recurrence in patients with NSCLC.
The correlation between fascin upregulation and metastatic
potential may be at least in part justified by the peculiar prevalence
of fascin expression in most neoplastic emboli inside blood vessels,
independent of the tumour type, and in most endothelial cells of
the pulmonary microvessels, but not of the major vessels. On the
other hand, the association between fascin expression and
occurrence of contralateral thoracic or distant metastases supports
the view that this molecule may be implicated in metastatic spread.
The metastasis mechanism could involve either direct vascular
permeation by actively migrating tumour cells or development of
newly formed microvessels highlighted by strong fascin immuno-
reactivity. In fact, a synergism between vascular invasiveness and
neoangiogenesis may actually favour metastatic spread. Further
work is in progress in our laboratory to test the possibility of using
fascin as a more suitable marker of neoangiogenesis than CD34 in
lung cancers. Although the molecular mechanisms of fascin
accumulation in tumour cell emboli of NSCLC still remain elusive,
fascin overexpression by neoplastic cells, either constitutive or
induced by yet unknown factors, may facilitate invasive tumour
growth, vascular permeation, and ultimately the appearance of
distant metastases.
In our study we did not try to compare directly the
immunostaining intensity for fascin with quantitative measure-
ments of the protein levels or the corresponding mRNA within
individual tumours. As a matter of fact, in order to elucidate the
prognostic role of fascin in NSCLC it was necessary to analyse
retrospectively a large series of tumours with long-term follow-up
(just like our series), and frozen tissue (the most suitable and
reliable material for RT-PCR assessment) had not been collected at
that time. Further studies, however, are in progress in our
laboratory to perform mRNA fascin analysis also in archival,
paraffin-embedded material. Although immunocytochemistry
cannot be strictly considered a tool of quantitative analysis, we
devised a simple three-tier semiquantitative scheme (negative, low,
and strong) by comparing tumour cell immunostaining with
internal positive controls (endothelial and dendritic cells) in order
to minimise bias because of the immunostaining variability and
the subjective impression of the slide readers. Our aim, however,
was not to demonstrate that differences in fascin immunostaining
intensity correlate with different levels of the protein (even though
that is likely), but that differences in immunostaining could be
reproducibly assessed to stratify the patients into different risk
categories. As a matter of fact, squamous cell carcinomas – that
showed the highest prevalence of fascin immunoreactivity with
86% of them being over 60% of immunolabelled cells – could be
easily subclassified according to fascin immunostaining intensity
into different prognostic categories. This suggests that different
levels of the protein may affect the biological behaviour of
squamous cell carcinoma.
In our study fascin was widely detected in most invasive
squamous cell carcinomas of the lung, though with variable
immunostaining intensity, whereas the protein was scarcely
expressed in in situ squamous cell carcinomas at different
anatomical sites (cervix, larynx, lung, and skin; data not shown).
In experimental models, it has been demonstrated that aggregates
of squamous cell carcinoma cells lose cell–cell junctions and
disperse via the selective induction of fascin-rich microspikes on
the cell surface because of interaction of a3b1 integrin with its
ligand laminin 5 elaborated by tumour cells themselves (Kawano
et al, 2001) and the activation of downstream signalling mechan-
ism involving the Rho-family small GTPase Cdc42 (Machesky and
Hall, 1997, Adams and Schwartz, 2000). Laminin 5 and a3b1
integrin are widely expressed in lung carcinomas, especially
squamous cell carcinomas, and at the epithelial–stromal interface
of tumour clusters (Bartolazzi et al, 1995; Maatta et al, 1999;
Catusse et al, 2000). In our study, we found that fascin
immunoreactivity was stronger in poorly differentiated squamous
cell carcinomas and at the leading edges of infiltrating horn pearls.
An increased production of laminin 5 has been reported also in
other types of human squamous cell carcinomas, especially in
tumours showing more infiltrative growth and poorer differentia-
tion (Ono et al, 1999; Haas et al, 2001; Yamamoto et al, 2001).
Therefore, we suggest that the increasing accumulation of fascin in
squamous cell carcinomas of the lung may be implicated not only
in the epithelial morphogenesis needed to tumour growth and
stromal invasion, but also in the development of metastases when
fascin is accumulated to some extent.
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